VistaGen Therapeutics (NASDAQ:VTGN) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of VistaGen Therapeutics (NASDAQ:VTGN) from a hold rating to a sell rating in a research report released on Saturday morning.

Other analysts have also issued reports about the stock. Stifel Nicolaus lowered shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a research report on Wednesday, December 17th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, VistaGen Therapeutics has an average rating of “Reduce” and a consensus target price of $0.95.

VistaGen Therapeutics Stock Performance

NASDAQ VTGN opened at $0.61 on Friday. The firm’s 50 day moving average price is $0.60 and its two-hundred day moving average price is $2.37. VistaGen Therapeutics has a twelve month low of $0.43 and a twelve month high of $5.14. The stock has a market cap of $24.13 million, a price-to-earnings ratio of -0.32 and a beta of 0.29.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.14 million. On average, research analysts forecast that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of institutional investors have recently modified their holdings of VTGN. Virtu Financial LLC bought a new stake in VistaGen Therapeutics during the 4th quarter valued at approximately $25,000. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics during the first quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of VistaGen Therapeutics in the third quarter valued at approximately $39,000. Seven Fleet Capital Management LP bought a new stake in shares of VistaGen Therapeutics in the fourth quarter valued at approximately $42,000. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of VistaGen Therapeutics in the fourth quarter worth $50,000. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.